← All trials
NCT07297186
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 21, 2017
- Primary completion
- Apr 10, 2023
- Completion date
- Apr 10, 2023
- First posted
- Dec 22, 2025
- Last posted
- Dec 22, 2025
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Minhai Biotechnology Co., LtdLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.